- Home
- APRE
as 12-20-2024 4:00pm EST
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DOYLESTOWN |
| Market Cap: | 15.8M | IPO Year: | 2019 |
| Target Price: | $15.50 | AVG Volume (30 days): | 22.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.15 - $8.85 | Next Earning Date: | 11-07-2024 |
| Revenue: | $1,310,839 | Revenue Growth: | 130.31% |
| Revenue Growth (this year): | 134.21% | Revenue Growth (next year): | -55.20% |
Stock Insider Trading Activity of Aprea Therapeutics Inc. Common stock (APRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gilad Oren | APRE | President/CEO | Oct 23 '24 | Buy | $3.92 | 500 | $1,957.50 | 333,395 | |
| Duey Marc | APRE | Director | Oct 18 '24 | Sell | $4.58 | 6,462 | $29,583.04 | 233,651 | |
| Duey Marc | APRE | Director | Oct 16 '24 | Buy | $4.39 | 30,000 | $131,700.00 | 240,113 | |
| Gilad Oren | APRE | President/CEO | Oct 15 '24 | Buy | $2.90 | 250 | $725.00 | 333,395 | |
| Duey Marc | APRE | Director | Oct 14 '24 | Buy | $2.58 | 190 | $490.20 | 240,113 | |
| Hamill John P. | APRE | SrVP/CFO/Prin Fin & Acct Ofcr | Oct 11 '24 | Buy | $2.46 | 50 | $123.19 | 19,368 | |
| Seizinger Bernd R. | APRE | Director | Oct 11 '24 | Buy | $2.68 | 10,000 | $26,800.00 | 44,730 | |
| Gilad Oren | APRE | President/CEO | Oct 10 '24 | Buy | $2.57 | 1,150 | $2,971.00 | 333,395 | |
| Hamill John P. | APRE | SrVP/CFO/Prin Fin & Acct Ofcr | Oct 10 '24 | Buy | $2.61 | 450 | $1,174.50 | 19,368 |
Latest Aprea Therapeutics Inc. Common stock News
APRE Breaking Stock News: Dive into APRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Zacks
a month ago
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
Simply Wall St.
a month ago
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
a month ago
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
a month ago
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Zacks
2 months ago
Pacira (PCRX) Q3 Earnings Beat Estimates
TipRanks
2 months ago
Aprea Therapeutics presents preliminary results on APR-1051
Simply Wall St.
2 months ago
Insider Spends US$132k Buying More Shares In Aprea Therapeutics
Compare APRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APRE Aprea Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.